Pre dose concentration [Regulatives / Guidelines]

posted by auditor – India, 2012-02-28 09:59 (5232 d 12:13 ago) – Posting: # 8173
Views: 12,097

Dear All,

As per recent EU guideline for BA/BE, clear statement given for not to withdraw any subject in which >5% Cmax concentration observed after dosing endogenous molecule.

I am looking for such kind of clarity in US FDA guidance. Can any one please let me know is the same thing can be followed in US submission?

Regards,

Auditor

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
367 visitors (0 registered, 367 guests [including 20 identified bots]).
Forum time: 23:13 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5